Novavax, in Milan in the queue at the hub where the new drug is administered

MILANO – It was the day of the undecided. After well over a year from the arrival of the first anti-Covid vaccines, yesterday many “gave in”. Without enthusiasm, indeed with a good dose of skepticism and certainly not booming numbers. But Novavax’s “Nuvaxovid” vaccine has in part succeeded where others have failed, in convincing dozens of people to file their latest alibis and overcome fears and resistance.